• roche logo

A new paradigm in the fight against cervical cancer.

HPV primary screening algorithm identifies more high grade disease than a Pap test alone and maintains screening efficiency.                                                       

The Case for Primary Screening 

Identify women at high-risk with HPV 16/18 genotyping.

Women with genotypes HPV 16 and 18 are at the greatest risk of developing high-grade cervical lesions.3            

Triage with Genotyping 

View the evidence base for HPV genotyping.

The ATHENA trial shows that 1 in 10 women positive for HPV 16 and/or 18 had high-grade cervical disease that was missed by cytology.4

ATHENA Trial Details 
  • Acronyms:


1. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst. 2005;97(9):675-683.

2. Andrae B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.J Natl Cancer Inst. 2008;100(9):622-629.

3. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.J Natl Cancer Inst. 2005;97(14):1072-1079.

4. Wright TC Jr, Stoler MH, Sharma A, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results.Am J Clin Pathol. 2011;136(4):578-586.